Patients with peritoneal carcinomatosis (PC) from colorectal origin may undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as a curative approach. One major prognostic factor that affects survival is completeness of cytoreduction. Molecular Fluorescence Guided Surgery (MFGS) is a novel intraoperative imaging technique that may improve tumor identification in the future, potentially preventing over-and under-treatment in these patients. This narrative review outlines a chronological overview of MFGS development in patients with PC of colorectal origin.
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| INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers worldwide, with an incidence of 40 patients per 100 000 population and a mortality rate of 15 per 100 000 persons. 1, 2 Of these patients,
8-25% develop peritoneal carcinomatosis (PC)
. [3] [4] [5] [6] Over the past decades, the treatment of PC of colorectal origin has evolved considerably, from palliative care toward a more successful treatment approach with curative intent. 7, 8 In particular, the introduction of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has contributed significantly to this change. 9, 10 After surgical cytoreduction of all macroscopic tumor tissue, the abdominal cavity is perfused with heated chemotherapy in order to eliminate remaining microscopic disease. Up to date, only one randomized clinical trial has been performed studying patients with PC of colorectal origin. A median overall survival of 22 months was seen for patients after undergoing CRS in combination with HIPEC, compared to 13 months for patients receiving only systemic chemotherapy with or without palliative surgery. 11, 12 The authors report a 5-years survival of 43% for patients in whom all macroscopic tumor was removed, compared to 0% for patients in whom residual lesions of more than 2.5 mm were left behind. 11 These findings emphasize the importance of patient selection and a macroscopically complete cytoreduction, mainly because incomplete cytoreduction followed by HIPEC does not contribute to a prolonged survival, but potentially does introduce a high risk of postoperative complications,
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an extensive rehabilitation period and subsequently decreased quality of life. [12] [13] [14] [15] Although the technical quality of the complete CRS/HIPEC procedure has improved, still up to 88% of the patients undergoing CRS and HIPEC for PC of CRC develop recurrent disease within 2 years. 16 Currently, many imaging modalities are available for preoperative staging, such as ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scans. Unfortunately, all of these imaging modalities are insufficient for the preoperative assessment of tumor load, or determination of a preoperative Peritoneal Cancer Index (PCI), the most important staging system in PC. CT, MRI, and fluorodeoxyglucose (FDG-) PET scans have a poor sensitivity and specificity to estimate PCI by detection of individual tumor deposits, due to the limited spatial resolution. 17 For example, the detection of individual peritoneal deposits using a CT-scan varies from 9.1 to 24.3% for tumor sizes <1 cm, to up to 59.3-66.7% for tumor size of over 5 cm. 18 These results are in accordance with other previous studies. [19] [20] [21] Current hybrid PET/ CT scanners have a limited spatial resolution of 5-8 mm, 22 whereas MRI seems to be more promising in detecting peritoneal lesions. 23 For intraoperative differentiation between benign and malignant lesions, surgeons currently depend on visual and tactile inspection only.
Unfortunately, the human eye and palpation are not competent enough to detect molecular changes in intra-abdominal lesions that have the same color and physical properties, or to distinguish tumor lesions from benign scar tissue originating from previous surgery. Today, to the best of our knowledge, no intraoperative imaging modalities provided by the more classical modalities like PET, are available to assist in the real-time identification of peritoneal cancer deposits, loco-regional metastases, and tumor-positive resection margins.
Considering the high tumor recurrence rates after the CRS and HIPEC procedure, there is a clear need for an imaging modality that can aid the oncological surgeon in the differentiation between tumor and benign tissue intraoperatively. In recent years, optical molecular imaging using tumor-targeted fluorescence tracers has emerged as a promising imaging technique for real-time guidance in oncological surgery. [24] [25] [26] This technique can be applied intraoperatively to serve as a "red-flag" imaging technique to assist in optimal tumor identification.
Improved detection of tumor tissue could not only help attain a more complete cytoreduction, but might also facilitate tailored surgery, avoiding unnecessary resections of benign lesions and organs.
This narrative review explains the principles of intraoperative optical molecular imaging and provides a chronological overview of the development of Molecular Fluorescence Guided Surgery (MFGS) in patients with PC of colorectal origin.
| PRINCIPLES OF INTRAOPERATIVE OPTICAL MOLECULAR IMAGING
In colorectal surgery, as in surgical oncology in general, radical surgery and tumor-free resection margins are essential for optimizing patient prognosis. Optical molecular imaging using fluorescence imaging agents can provide real-time intraoperative feedback with high resolution, that is in concordance with the natural surgical field of view of a surgeon and based on the molecular characteristics of the tissue ( Figure 1 ). The technique makes use of non-ionizing imaging agents and can be implemented relatively easily in the current surgical workflow.
Over the past decades, there has been an increased interest in the clinical application of optical molecular imaging using fluorescence imaging agents. Fluorescence occurs when a photon or fluorescent dye absorbs light at a certain wavelength, subsequently triggering the release of a photon with a longer wavelength. 27 The quality of can roughly be divided into non-targeted and targeted imaging agents.
The effect of non-targeted imaging agents is mainly based on vascularization and perfusion (ie, also the so-called Enhanced Permeability and Retention (EPR) effect), whereas targeted imaging agents specifically bind to a receptor or protein that is present in a tumor cell. Due to genetic alterations that occur in cancer development, various receptors and proteins become upregulated, which can potentially be used as targets for imaging purposes. 39 Prior to developing such targeted imaging agents, it is essential to identify which genes or proteins become upregulated for each specific tumor type.
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| UPREGULATED GENES AND PROTEINS RELATED TO CRC
The potential application of targeted imaging agents for intraoperative tumor visualization is dependent on the expression levels of biomarkers. A biomarker is a specific component present on or secreted by the tumor cell itself.
Most colorectal cancers are thought to develop via the "adenomato-carcinoma sequence," arising from normal cells through the stepwise asset of different genetic alterations. 42, 43 In these expressed genes different functional categories can be identified: genes related to proliferation and metabolic rates, to cell adhesion and communication, to transcription and mitosis regulation, or to apoptosis. 44, 45 Knowing which biomarkers are encoded by which genes is important when searching for which target to develop a fluorescence imaging agent for.
Cardoso et al 44 presented a list of 128 different genes that were found to be upregulated in CRC compared to normal colorectal tissue.
Since protein expression is not always synchronously upregulated, not all of these genes result in overexpression of the related proteins or receptors. Previously, an extensive literature search has been performed on this specific list of genes, in order to identify which genes gave an upregulation of the related proteins or receptors as confirmed by immunohistochemical analysis. 46 As a result, 29 targets were identified, that could be used for imaging purposes during CRC surgery.
| TARGET SELECTION CRITERIA (TASC)
To select the most optimal target for imaging purposes from this large set of upregulated biomarkers, the TArget Selection Criteria (TASC)
scoring system was developed. 46 The aim of the TASC was to improve As mentioned before, 29 targets were identified that may be used as potential targets for intraoperative imaging of CRC. 46 Using the TASCscoring system, six biomarkers were considered the most promising: 
| FLUORESCENCE IMAGING AGENTS
As stated before, fluorescence imaging agents or probes that can be used for MFGS can roughly be divided into two categories:
non-targeted fluorescent probes and targeted fluorescent probes.
The main difference between these two categories is based on their mechanism of action (MOA).
| Non-targeted fluorescent probes
Non-targeted fluorescent probes accumulate "passively" in solid tumors due to physiological properties such as increased angiogenesis, pressure differences, and high metabolic activity The first potential application of ICG-based fluorescence imaging in patients with peritoneal metastases of colorectal origin was demonstrated in 2016. 71 In this study, peritoneal metastases from non-mucinous adenocarcinoma were accurately identified following the intravenous administration of free ICG during surgery, leading to an adjustment in clinical decision making in 29% of patients. However, the benefit was minimal in patients with mucinous adenocarcinoma.
Despite the positive results demonstrated in this study, the main disadvantage still lies in the fact it is not tumor-specific and therefore leads to a low sensitivity and specificity.
| Targeted fluorescent probes
Due to the low sensitivity and specificity of non-targeted fluorescence probes, its application in surgical oncology is still limited. Therefore, to increase contrast, this resulted in a shift toward the development and clinical translation of targeted optical imaging agents enhancing surgical vision based on the molecular characteristics of cancer cells.
The MOA of targeted fluorescent probes is based on the concept of a carrier molecule that is conjugated to a fluorescent dye, specifically binding to a certain tumor target. Carrier molecules can either be monoclonal antibodies, (small) peptides, small molecules, or other molecules that specifically target certain cell surface markers that become overexpressed due to genetic variances that occur in every tumor ( Figure 3B ). 72 Moreover, the increased metabolic activity that characterizes certain tumor types can be used as a target. 40 Besides a suitable carrier molecule, the fluorescent dye itself also plays an important role. The development of new fluorescence probes is challenging since each agent needs separate regulatory approval, which is an expensive and time-consuming process. 73 As mentioned before, fluorescent dyes that emit light folate-FITC, targeting the folate receptor α. Ever since, targeted optical imaging has been applied for many different indications.
| POTENTIAL FLUORESCENCE IMAGING AGENTS FOR DETECTION OF COLORECTAL CANCER
As mentioned before, using the TASC scoring system, seven potential targets for optical molecular imaging of PC of colorectal origin have been identified: CXCR4, EpCAM, EGFR, CEA, Muc1, MMPs, and VEGF-A. 46 The specifics of these proteins and receptors are summarized in Table 1 . (NCT02583568), and esophageal cancer. 108 The feasibility of MFGS using bevacizumab-800CW is also being investigated for intraoperative guidance in benign diseases such as endometriosis (NCT02975219) or for endoscopic detection of familial adenomatous polyposis (NCT02113202).
In CRC and specifically peritoneal metastases of colorectal origin, so far two phase-I feasibility studies have been performed in humans.
| FEASABILITY STUDIES IN PC OF COLORECTAL ORIGIN
In 
110-115
The specificity in these two feasibility studies appears to be relatively low, with a substantial amount of false positive lesions when applying intraoperative fluorescence imaging. This might be due to technical limitations of the fluorescence camera system that still need to be improved, such as the multispectral substration techniques.
Currently, quantification of fluorescence with most of the present generation of clinically approved fluorescence camera systems is still limited, making the interpretation of fluorescence signals subjective. If a threshold could be set to give the surgeon a "yes" or "no" answer to the question whether a peritoneal lesion is tumor-positive with a certain sensitivity and specificity, this could potentially improve interpretation of fluorescence signals. Last, for some tracers, the optimal dose might still need further optimization. 107 Additional research and studies need to be performed to investigate novel fluorescence imaging agents in humans for MFGS of PC of colorectal origin. Theoretically, multiple fluorescence imaging agents can be intravenously administered to the same patients simultaneously, a so-called "tracer cocktail," in order to improve sensitivity and specificity. Therefore, novel fluorescence imaging agents need to be validated in a standardized way, with the emphasis [106] [107] [108] [109] on the determination of the safety, feasibility, optimal agent dose, and optimal timing for surgical intervention in phase-I feasibility studies. 
| Novel fluorescence imaging probes
Next to the validation of potential targets for imaging, novel fluorescent probes are being developed. Figures 3C and D) . 118 On the other hand, smaller molecules are in general more difficult to conjugate to a fluorescence dye, as even small structural changes can influence pharmacokinetics and binding efficacy significantly. 118, 119 Another subgroup of imaging probes has come forward in recent years: targeted smart-activatable probes ( Figure 3E ). 119 The working mechanism of these probes is based on the principle of photochemical quenching or ligand-targeted activation. Smart activatable probes only fluoresce when bound to the tumor or cleaved by specific proteases or peptidases excreted by the tumor, which improves signal-to-background ratios due to limited background fluorescence. 118, 120 The first clinical studies to investigate smart activatable probes have been performed already. 117 However, to the best of our knowledge, this has not yet been done for intraoperative imaging of CRC or PC of colorectal origin.
A similar "on-or-off" concept has been applied in the development of a pH-activatable fluorescent probe. This probe becomes activated upon contact with a certain threshold pH (pH ≤ 6.9), as the majority of solid tumors are acidotic. Although this probe does not target a tumor biomarker, it is still highly specific due to the pH transistor concept. 121 The benefit of such a probe is that it can be applied in a broad range of oncological indications. However, the first proof-of-concept in human study using a pH-activated probe still needs to be conducted. 
| Photodynamic therapy
Although current clinical studies are mainly aimed to investigate the feasibility of optical imaging for cancer detection, in the future intraoperative imaging may also be used as a therapeutic modality.
Carrier molecules that specifically target the tumor can also be labeled to a photoactive dye (ie, photosensitizer), to allow targeted photodynamic therapy (tPDT). When excited with light of a specific wavelength, photosensitizers not only fluoresce, but also form reactive oxygen species that oxidize the cells they target, thereby killing them. 122 Potentially, tPDT may be applied after CRS, to assist in the elimination of microscopic peritoneal lesions. As there is only superficial activation of the targeted photosensitizers, side-effects are estimated to be limited. The first clinical trials have already been performed to investigate the safety and feasibility of tPDT using a variety of different photosensitizers. Phase I and II clinical trials have been conducted for treatment of colorectal cancer, 123 pelvic recurrence of CRC, 124 colorectal liver metastases (NCT00068068), 125 and locally advanced rectal cancer. 126 Moreover, tPDT has also been applied for the treatment of peritoneal metastases originating from ovarian cancer and sarcomas, 127 and different gastrointestinal tumors 128 with promising results. These studies demonstrate that tPDT could potentially be used as an effective treatment for both CRC and PC. However, future studies are required to determine the effect on PC of colorectal origin, when combined with MFGS.
| CONCLUSION
In conclusion, treatment of PC of colorectal origin with curative intent 
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